release of ic3b from apoptotic pancreatic tumor cells induces tolerance by binding to immature...

1
BioMed Central TIONAL INTERNA CANCER CELL Page 1 of 1 (page number not for citation purposes) Cancer Cell International Open Access Poster presentation Release of iC3b from apoptotic pancreatic tumor cells induces tolerance by binding to immature dendritic cells J Schmidt, MW Büchler and A Märten* Address: Department of Surgery, University of Heidelberg, Germany Email: A Märten* - [email protected] * Corresponding author Background & Aims Chemo- as well as immunotherapeutical approaches induce apoptosis in tumor cells. Apoptotic cells are known to activate homologous complement and to be opsonized with iC3b. Since maturation of dendritic cells (DC) can be inhibited by binding of iC3b to the comple- ment receptor 3 (CR3, CD11b/CD18) and because imma- ture DC induce tolerance, we investigated the induction of tolerance after pulsing DC with apoptotic cells in the pres- ence or absence of native serum. Methods Apoptosis in pancreatic carcinoma cells was induced either by heat-stress, chemotherapy or anti-Her2 anti- body. Monocyte-derived DC were pulsed with apoptotic cells with or without native serum. DC were analyzed for the maturation state by flow cytometry and the cytotoxic activity was determined. Tolerance was prevented by addi- tion of substances such as anti CD11b or N-acetyl-D-glu- cosamine (NADG) which block iC3b binding to CR3. Results All of the former strategies for apoptosis induction resulted in iC3b release. Pulsing DC with apoptotic cells in the presence of serum prevents maturation of DC and induces finally tolerance. This tolerance could be pre- vented almost completely by blocking the interaction of iC3b with the CR3 receptor. from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2 nd Annual Meeting Mainz, Germany, 6–7 May 2004 Published: 1 July 2004 Cancer Cell International 2004, 4(Suppl 1):S24 Received: 28 April 2004 <supplement> <title> <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2<sup>nd </sup>Annual Meeting</p> </title> <note>Meeting abstracts</note> </supplement> This article is available from: http://www.cancerci.com/content/4/S1/S24

Upload: j-schmidt

Post on 06-Jul-2016

224 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Release of iC3b from apoptotic pancreatic tumor cells induces tolerance by binding to immature dendritic cells

BioMed CentralC

TIONALINTERNACANCER CELL

Page 1 of 1(page number not for citation purposes)

Cancer Cell International

Open AccessPoster presentationRelease of iC3b from apoptotic pancreatic tumor cells induces tolerance by binding to immature dendritic cellsJ Schmidt, MW Büchler and A Märten*

Address: Department of Surgery, University of Heidelberg, Germany

Email: A Märten* - [email protected]

* Corresponding author

Background & AimsChemo- as well as immunotherapeutical approachesinduce apoptosis in tumor cells. Apoptotic cells areknown to activate homologous complement and to beopsonized with iC3b. Since maturation of dendritic cells(DC) can be inhibited by binding of iC3b to the comple-ment receptor 3 (CR3, CD11b/CD18) and because imma-ture DC induce tolerance, we investigated the induction oftolerance after pulsing DC with apoptotic cells in the pres-ence or absence of native serum.

MethodsApoptosis in pancreatic carcinoma cells was inducedeither by heat-stress, chemotherapy or anti-Her2 anti-body. Monocyte-derived DC were pulsed with apoptoticcells with or without native serum. DC were analyzed forthe maturation state by flow cytometry and the cytotoxicactivity was determined. Tolerance was prevented by addi-tion of substances such as anti CD11b or N-acetyl-D-glu-cosamine (NADG) which block iC3b binding to CR3.

ResultsAll of the former strategies for apoptosis inductionresulted in iC3b release. Pulsing DC with apoptotic cellsin the presence of serum prevents maturation of DC andinduces finally tolerance. This tolerance could be pre-vented almost completely by blocking the interaction ofiC3b with the CR3 receptor.

from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual MeetingMainz, Germany, 6–7 May 2004

Published: 1 July 2004

Cancer Cell International 2004, 4(Suppl 1):S24

Received: 28 April 2004<supplement> <title> <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2<sup>nd </sup>Annual Meeting</p> </title> <note>Meeting abstracts</note> </supplement>

This article is available from: http://www.cancerci.com/content/4/S1/S24